Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS SC Actinic Keratosis Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    ACTINIC KERATOSIS - SCORE

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This South Carolina PDP step-therapy policy governs coverage of diclofenac sodium gel 3% for actinic keratosis. New starts require a trial of either topical fluorouracil or topical imiquimod.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyACTINIC KERATOSIS - SCORE
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionBefore requesting diclofenac sodium gel 3%, document a trial of either topical fluorouracil or topical imiquimod.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1Affected product
    2Alternative topical therapies
    1Step-therapy trial required

    Coverage Criteria

    Actinic Keratosis Initial Therapy

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage requires the stated step-therapy criterion.

    Prior topical therapy trial

    • Topical fluorouracil trial: Trial of topical fluorouracil.
    • Topical imiquimod trial: Trial of topical imiquimod.

    Initial Therapy

    New starts require the following step.

    New-start step therapy: Trial of generic zonisamide capsule.

    Step applies to new starts only.

    Continuation Therapy

    Continuation therapy may be approved.

    Continuation therapy: Prior therapy with Zonisade may be continued.

    Approve for continuation of prior therapy.

    Provider Actions

    Step Therapy

    Topical Trial Required Before Diclofenac

    Before coverage of diclofenac sodium gel 3% for actinic keratosis, document a trial of topical fluorouracil or topical imiquimod.

    Step Therapy

    Document One Required Topical Therapy Trial

    For patients seeking diclofenac sodium gel 3% coverage, document a trial of one of the following topical therapies: fluorouracil or imiquimod.

    • Topical fluorouracil
    • Topical imiquimod
    Documentation Required

    Zonisamide Step Applies to New Starts Only

    For a new start, document a trial of generic zonisamide capsules. This step requirement applies only to new starts; approve continuation of prior zonisamide therapy when continuation is documented.

    • New starts: generic zonisamide capsule trial required
    • Continuing therapy: document prior therapy; the new-start step does not apply
    Denial Risk

    Denial Risk: Missing Topical Trial Documentation

    Coverage may be denied when neither required topical trial is documented before requesting diclofenac sodium gel 3% for actinic keratosis.

    • Document a trial of topical fluorouracil or topical imiquimod in the medical record.
    • Do not submit the diclofenac sodium gel 3% request without documentation of one qualifying topical trial.

    Background

    This policy addresses actinic keratosis and applies to diclofenac sodium gel 3%. Coverage places diclofenac sodium gel 3% after a trial of one of two topical therapies: topical fluorouracil or topical imiquimod.

    Initial Therapy Criteria

    Diclofenac Sodium Gel 3% Initial Coverage

    Diclofenac sodium gel 3% requires a trial of either topical fluorouracil or topical imiquimod.

    Required prior topical therapy

    • Fluorouracil option: Trial of topical fluorouracil.
    • Imiquimod option: Trial of topical imiquimod.

    Initial Therapy

    New starts require a trial of generic zonisamide capsules.

    Required prior trial: Trial of generic zonisamide capsule.

    Step applies to new starts only.

    Continuation Criteria

    Continuation of Prior Therapy

    Continuation of prior therapy is approvable.

    Continuation therapy: Approve for continuation of prior therapy.

    The step requirement applies to new starts only.

    Step-Therapy Requirements

    StepRequired trialApplies to
    1Trial of either topical fluorouracil or topical imiquimod before diclofenac sodium gel 3%Diclofenac sodium gel 3% for actinic keratosis
    StepRequired trialApplicability
    1Trial of generic zonisamide capsuleNew starts only; continuation of prior therapy may be approved
    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyACTINIC KERATOSIS - SCORE
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionBefore requesting diclofenac sodium gel 3%, document a trial of either topical fluorouracil or topical imiquimod.
    SourceLink
    On This Page
    Coverage CriteriaProvider ActionsBackgroundInitial Therapy CriteriaContinuation CriteriaStep-Therapy Requirements